People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Today, we're diving into a hot topic in the world of health and wellness: semaglutide. You might have heard about this ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...

GLP-1RAs were associated with a reduced risk for neurodegenerative and cerebrovascular diseases in type 2 diabetes and obesity.

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...